Free Trial
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

$0.70
0.00 (0.00%)
(As of 07/19/2024 ET)
Today's Range
$0.70
$0.73
50-Day Range
$0.45
$0.74
52-Week Range
$0.25
$1.19
Volume
11,428 shs
Average Volume
165,755 shs
Market Capitalization
$24.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ORGS stock logo

About Orgenesis Stock (NASDAQ:ORGS)

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

ORGS Stock Price History

ORGS Stock News Headlines

[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Orgenesis Provides Year End Business Update
[URGENT] Altcoin Winning Picks
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Orgenesis Inc. (ORGS)
Orgenesis Inc ORGS
See More Headlines
Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/21/2024
Today
7/19/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ORGS
Fax
N/A
Employees
146
Year Founded
2008

Profitability

Net Income
$-55,360,000.00
Net Margins
-1,343.97%
Pretax Margin
-692.54%

Debt

Sales & Book Value

Annual Sales
$530,000.00
Book Value
($0.66) per share

Miscellaneous

Free Float
32,497,000
Market Cap
$24.12 million
Optionable
Optionable
Beta
1.23

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Ms. Vered Caplan M.Sc. (Age 55)
    Chairperson of the Board, CEO & President
    Comp: $341.38k
  • Prof. Sarah Ferber Ph.D. (Age 70)
    Founder & Chief Scientific Officer
    Comp: $268.32k
  • Mr. Victor Miller (Age 54)
    CFO, Secretary & Treasurer
  • Pierre Lammeretz
    Interim Chief Operating Officer
  • Dr. Shimon Hassin Ph.D.
    Chief Technology Officer
  • Mr. Evan Fishman
    Chief Financial Officer of Orgenesis Biotech
  • Mr. Joseph Carpinelli
    Chief Financial Officer of Octomera

ORGS Stock Analysis - Frequently Asked Questions

How have ORGS shares performed this year?

Orgenesis' stock was trading at $0.5007 on January 1st, 2024. Since then, ORGS shares have increased by 39.8% and is now trading at $0.70.
View the best growth stocks for 2024 here
.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) released its quarterly earnings data on Tuesday, May, 21st. The company reported ($0.29) earnings per share (EPS) for the quarter. The firm had revenue of $0.14 million for the quarter.

Does Orgenesis have any subsidiaries?

Orgenesis subsidiaries include these companies: Koligo Therapeutics, and Tamir Biotechnology Inc.

How do I buy shares of Orgenesis?

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORGS) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners